Terapevticheskii arkhiv · 2001
[Effects of pathogenetic therapy on blood cholesterol in patients with glomerulonephritis].
Сравнительное исследованиеАннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Neverov N I, Stavrovskaia E V, Kolina I B, Shvetsov M Iu, Zakharova E V, Shilov E M
Аннотация
AIM: To evaluate effects of corticosteroids, cytostatics, ACE inhibitors, Ang-II receptor blockers, HMG-CoA-reductase inhibitors on the levels of blood cholesterol in patients with progressive glomerulonephritis (PGN).
MATERIAL AND METHODS: The influence of medications which are used for treatment of chronic glomerulonephritis on the serum levels of total cholesterol (TCh) was investigated in 53 patients with chronic glomerulonephritis and persistent nephrotic syndrome (NS). All the patients with NS or nephrotic range proteinuria were divided into five groups depending on the type of therapy: corticosteroids, cytotoxic agents, ACE inhibitors, Ang-II receptor blocker, HMG-CoA-reductase inhibitors.
RESULTS: No negative change of serum TCh was revealed after the courses of treatment with corticosteroids and cytotoxic agents. Moreover, treatment with ACE inhibitors and Ang-II receptor blockers was accompanied with a significant reduction of the TCh level.
CONCLUSION: ACE inhibitors and Ang-II receptor blockers affect some mechanisms of glomerulonephritis progression including hypercholesterolemia.
MATERIAL AND METHODS: The influence of medications which are used for treatment of chronic glomerulonephritis on the serum levels of total cholesterol (TCh) was investigated in 53 patients with chronic glomerulonephritis and persistent nephrotic syndrome (NS). All the patients with NS or nephrotic range proteinuria were divided into five groups depending on the type of therapy: corticosteroids, cytotoxic agents, ACE inhibitors, Ang-II receptor blocker, HMG-CoA-reductase inhibitors.
RESULTS: No negative change of serum TCh was revealed after the courses of treatment with corticosteroids and cytotoxic agents. Moreover, treatment with ACE inhibitors and Ang-II receptor blockers was accompanied with a significant reduction of the TCh level.
CONCLUSION: ACE inhibitors and Ang-II receptor blockers affect some mechanisms of glomerulonephritis progression including hypercholesterolemia.
Предметные рубрики MeSH
AdultAngiotensin IIAngiotensin-Converting Enzyme InhibitorsAnti-Inflammatory AgentsAnticholesteremic AgentsAntihypertensive AgentsAzathioprineCaptoprilCholesterolCreatinineCyclophosphamideData Interpretation, StatisticalEnalaprilFemaleGlomerulonephritisHumansImmunosuppressive AgentsLovastatinMaleNephrotic SyndromePrednisoloneRetrospective StudiesTetrazolesTime FactorsValineValsartan